MA-BOS-BIOMED/FACT-CRO
7.1.2019 12:02:06 CET | Business Wire | Press release
Factory-CRO Group , a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and Boston Biomedical Associates (BBA) a premier full-service Medical Device/Biotechnology CRO and Consultancy based in the United States announce that they have merged the organizations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190107005358/en/
The merger further advances the shared strategic vision to become the leading Global Medical Device and Medical Technology focused CRO. Following the recent acquisitions of MileStone Research Organization, Five Corners, and Clinical Device Group the Factory-CRO Group now has specialized operations and expertise in the United States, Australia/New Zealand, and Europe. This global expansion coupled with the diverse medical therapeutic expertise provides a means to efficiently service clients.
“BBA is excited to join Factory-CRO’s worldwide group as it will allow us to expand our comprehensive service offering to our clients,” said Lauren Baker, PhD, President and CEO of BBA. “The alignment of Factory-CRO and BBA’s core values and approach to engagements combined with our collective therapeutic competencies ensures that our clients now have improved access to our global clinical trial execution resources, and our regulatory and medical expertise.” Dr. Baker then added, “We are able to fully support our clients as their needs evolve and they strive to help patients globally.”
“We are honored to have the BBA team join the Factory-CRO Group,” said Dirk Meijer, MD, MSc,PhD, Factory-CRO CEO. “BBA’s ability to provide CRO/Consultative service in North America was a missing link in our global offerings.” Dr. Meijer then added, “Our clients have consistently asked us to expand our offerings in North America. This merger allows us to provide our specialized expertise and a continued commitment to the highest level of customized service to a larger audience. Now we are the only Medical Device and Medical Technology CRO that offers services in United States, Europe, Australia and New Zealand. We operate from our own offices located within each region housed with employees that have refined expertise to meet our unique client needs.”
About Factory-CRO Group:
Factory-CRO
Group is a leading, full-service contract research organization focused
on the management of clinical studies for medical devices, IVDs,
biologics and device-drug combination products internationally. Founded
in 1992, the business offers a full suite of trial management services
to its global client base across a broad range of therapeutic areas,
including orthopedic, cardiovascular, dermatology and aesthetics.
Current members of Factory-CRO Group are: BBA, Five Corners CRO,
Milestone Research group and Factory-CRO.
For more information about Factory-CRO, visit their website, www.factory-cro.com or contact Joris Bannenberg, MD, PhD, Factory-CRO’s CMO:
Joris Bannenberg, MD, PhD
CMO
j.bannenberg@factory-cro.com
+31
30 229 2727 (x108)
About Boston Biomedical Associates:
Boston
Biomedical Associates (BBA) is a premier full-service Medical
Device/Biotechnology CRO and Consultancy firm. Founded in 2000, by
Lauren Baker, Ph.D., this leading CRO has earned a reputation for its
comprehensive approach to clinical trial execution services to its
global client base across a broad range of therapeutic areas, including
orthopedic, cardiovascular, endocrine and neurologic disorders.
For more information about BBA, visit their website, www.bbacro.com or contact Mack Rubley, PhD, BBA’s Vice President of Business Development and Marketing:
Mack D. Rubley, PhD
VP, Business Development and Marketing
702-808-3494
mrubley@bbacro.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20190107005358/en/
Contact:
Joris Bannenberg, MD, PhD CMO j.bannenberg@factory-cro.com +31 30 229 2727 (x108)
Mack D. Rubley, PhD VP, Business Development and Marketing 702-808-3494 mrubley@bbacro.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
The 2026 NAB Show Wraps with Proof the Future of Media and Entertainment is Expanding Beyond Broadcasting23.4.2026 01:52:00 CEST | Press release
The Show’s growing community of creators, enterprise media teams and leaders in sports media is driving the next era of storytelling The 2026 NAB Showwrapped today, welcoming more than 58,000 registered attendees and reaffirming its place at the center of the global media and entertainment evolution. Driven by an expanding community of creators, enterprise media teams and leaders in sports media, the Show has brought in new audiences and sparked new collaborations. The 2026 NAB Show didn’t just reflect where the industry is; it pushed it forward, strengthening its status as the must-attend marketplace for the future of storytelling and content innovation. “The 2026 NAB Show captured the energy and transformation driving today’s media and entertainment landscape, unveiling powerful new tools and technologies that put storytelling in everyone’s hands,” said Karen Chupka, executive vice president of NAB Show. “This year, we brought together a truly global community to spark innovation, el
ASP Announces Strategic Partnership With ChemDAQ to Advance Safety, Confidence, and Compliance in Sterile Processing23.4.2026 01:42:00 CEST | Press release
Advanced Sterilization Products (ASP), a global leader in infection prevention and low‑temperature sterilization, today announced a strategic partnership with ChemDAQ, a leading provider of hazardous gas detection and monitoring solutions. Together, ASP and ChemDAQ will support healthcare organizations by strengthening safety practices, reinforcing regulatory confidence, and advancing best‑in‑class sterile processing environments. As part of this partnership, ASP and ChemDAQ collaborated on evidence rooted in industry engagement and thought leadership to help sterile processing professionals stay ahead of evolving standards and guidance, including AAMI ST58 and other recommendations related to sterilant exposure and workplace safety. These efforts underscore ASP’s commitment to continuous improvement and practical innovation that meets real‑world needs. This collaboration reflects ASP’s role as a trusted advisor to sterile processing professionals, bringing together proven low‑temperat
TSMC Debuts A13 Technology at 2026 North America Technology Symposium22.4.2026 21:00:00 CEST | Press release
Newest Node Pushes Density Scaling and Energy Efficiency to New Heights to Address Industry’s Most Demanding Applications TSMC (TWSE: 2330, NYSE: TSM) today debuted its latest innovation in its most advanced process technology at the Company’s 2026 North America Technology Symposium. TSMC’s new A13 process is a direct shrink of its industry-leading A14 node announced in 2025, enabling even more compact and efficient designs to address insatiable customer demand in computational requirements for next-generation artificial intelligence, high-performance computing (HPC), and mobile applications. Representing TSMC’s commitment to continuous improvement, A13 provides 6% area savings from A14. Design rules are fully backward compatible with A14, enabling customers to quickly migrate their designs to TSMC’s latest nanosheet transistor technology. In addition, A13 delivers increased power efficiency and performance gains through design-technology co-optimization, and is scheduled to enter prod
Galderma Shareholders Approve All Annual General Meeting Proposals22.4.2026 17:45:00 CEST | Press release
Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, announced that shareholders approved all proposals put forward by the Board of Directors at its Annual General Meeting (AGM), held earlier today via live webcast. This includes the payment of a gross dividend of 0.35 CHF per dividend-bearing share1, to be distributed out of reserves from capital contributions. Shareholders approved the election of Harry Kirsch as independent member of the Board of Directors, as well as the election of Samuel du Retail and Delphine Viguier-Hovasse, representatives of L’Oréal, as non-independent members of the Board. In addition, Thomas Ebeling (Chair), Daniel Browne, Maria Teresa Hilado, Karen Lee Ling, Roberto Marques, Sherilyn McCoy and Dr. Flemming Ørnskov were re-elected to the Board. The AGM also approved the company’s 2025 Annual Financial Statements, Non-Financial Report and Compensation Report. Detailed voting results and the official minutes will be published on Galderma's
Altrove and Bloomineral Named Winners of the 2026 Grand Prix ACF AutoTech22.4.2026 15:21:00 CEST | Press release
IoT.Bzh receives the inaugural Industrialization Prize at the 9th edition of the international automotive startup competition Altrove and Bloomineral have been crowned winners of the 2026 Grand Prix ACF AutoTech, the international startup competition recognizing the best of automotive innovation. The ninth edition was held on Wednesday, April 15 at the Automobile Club de France in Paris, where IoT.Bzh also received the first-ever Industrialization Prize. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260422236542/en/ Picture of the end of the event with the winners : Bloomineral, Altrove and Iot.Bzh + all the Jury Members from French Automotive OEM and Tier1 Hosted by competition founder Richard de Cabrol and Simon Degiovanni, the evening gathered more than 250 leaders from the automotive, technology, digital, business and media sectors, with attendees joining both on-site and online. Six finalist startups, selected from mor
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
